NEW YORK STATE MEDICAID PROGRAM – DISPENSE BRAND DRUGS WHEN LESS EXPENSIVE

On April 26, 2010, New York Medicaid implemented a new cost containment initiative which promotes the use of certain multi-source brand name drugs when the cost of the brand name drug is less expensive than the generic equivalent.

Current list of Brand name drugs included in this program* (Date Revised 8/09/2011):

- Adderall XR
- Aricept 5mg, 10mg ODT
- Astelin
- Carbatrol
- Diastat
- Duragesic
- Lovenox
- Nasacort AQ
- Valtrex

*List is subject to change

Please be aware that Brand name drugs included in this program:

- will not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription; and do not need to be billed using the NCPDP (408-D8) Dispense As Written/Product Selection Code of ‘1’.
- have a generic copayment; and are therefore in conformance with State Education Law which intends that patients receive the lower cost alternative;
- have an enhanced dispensing fee (equal to generic dispensing fee);
- will be paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (neither the SMAC nor FUL will be applied);
- will not require prior authorization.

Please keep in mind that drugs removed from this program may be subject to prior authorization requirements of other pharmacy programs; again promoting the use of the most cost-effective product.